These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis. Wang Z; Jin X; Zeng J; Xiong Z; Chen X Ann Hematol; 2024 Mar; ():. PubMed ID: 38494551 [TBL] [Abstract][Full Text] [Related]
26. Current and emerging therapies in primary myelofibrosis. Ayyappan S; Janakiram M; Raghupathy R Cardiovasc Hematol Disord Drug Targets; 2012 Sep; 12(1):6-20. PubMed ID: 22746348 [TBL] [Abstract][Full Text] [Related]
27. Treatment of Myelofibrosis: A Moving Target. Cerquozzi S; Farhadfar N; Tefferi A Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017 [TBL] [Abstract][Full Text] [Related]
28. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ostojic A; Vrhovac R; Verstovsek S Ther Clin Risk Manag; 2012; 8():95-103. PubMed ID: 22399854 [TBL] [Abstract][Full Text] [Related]
29. Beyond JAK inhibitor therapy in myelofibrosis. Odenike O Hematology Am Soc Hematol Educ Program; 2013; 2013():545-52. PubMed ID: 24319230 [TBL] [Abstract][Full Text] [Related]
30. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Tefferi A Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049 [TBL] [Abstract][Full Text] [Related]
31. Stem cell transplant for the treatment of myelofibrosis. Mannelli L; Guglielmelli P; Vannucchi AM Expert Rev Hematol; 2020 Apr; 13(4):363-374. PubMed ID: 32077336 [No Abstract] [Full Text] [Related]
32. Management of Myelofibrosis: from Diagnosis to New Target Therapies. Iurlo A; Cattaneo D; Bucelli C Curr Treat Options Oncol; 2020 Apr; 21(6):46. PubMed ID: 32350623 [TBL] [Abstract][Full Text] [Related]
33. Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors. Fauble V; Leis J; Mesa RA Leuk Suppl; 2012 May; 1(Suppl 1):S2-7. PubMed ID: 27175229 [TBL] [Abstract][Full Text] [Related]
34. Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis. Barosi G; Rosti V; Gale RP Onco Targets Ther; 2015; 8():1091-102. PubMed ID: 26056473 [TBL] [Abstract][Full Text] [Related]
35. How I treat symptomatic splenomegaly in patients with myelofibrosis. Mesa RA Blood; 2009 May; 113(22):5394-400. PubMed ID: 19332765 [TBL] [Abstract][Full Text] [Related]
36. [Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review]. Liu JX; Chen W; Xu KL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):283-286. PubMed ID: 29397859 [TBL] [Abstract][Full Text] [Related]
37. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459 [TBL] [Abstract][Full Text] [Related]
38. Myelofibrosis and allogeneic transplantation: critical points and challenges. Ranalli P; Natale A; Guardalupi F; Santarone S; Cantò C; La Barba G; Di Ianni M Front Oncol; 2024; 14():1396435. PubMed ID: 38966064 [TBL] [Abstract][Full Text] [Related]
39. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? Chen E; Mullally A Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):268-76. PubMed ID: 25696866 [TBL] [Abstract][Full Text] [Related]
40. Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. Ecsedi M; Schmohl J; Zeiser R; Drexler B; Halter J; Medinger M; Duyster J; Kanz L; Passweg J; Finke J; Bethge W; Lengerke C Ann Hematol; 2016 Oct; 95(10):1627-36. PubMed ID: 27480090 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]